CIHRT Exhibit P-1830 Page 1

Similar documents
Wpe1 1218/2007. Message CIHRT Exhibit P-1831 Page 1. Page I of I

Quality Indicators - Anatomic Pathology- HSC/STC Jul-Sep 2 nd Qtr. Apr-Jun 1 st Qtr

Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

NordiQC External Quality Assurance in Immunohistochemistry

Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use

Single and Multiplex Immunohistochemistry

Quality assurance and quality control in pathology in breast disease centers

Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers

IHC Polymer. BioGenex Website. Presented for: Presented by: Date: BioGenex Tech Support 2016

Urothelial Carcinoma (UC)

Appendix 1. A. Procedure for preparing histopathology slides. The liver removed and stored immediately in buffered formalin 10 % for

Pepsin Solution ready-to-use

Quality Assurance and Quality Control in the Pathology Dept.

The Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast Carcinoma

Urothelial Carcinoma (UC)

ACRIN 6666 Therapeutic Surgery Form

What kind of material should we use for ICC in our daily routine. Torill Sauer Department of Pathology, Akershus University Hospital

Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology

CC01 - Colon Cancer Tissue Microarray

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

Cost Effectiveness of Manual Tissue Microarray Technique in Diagnostic Immunohistochemistry

A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues

Providence Medford Medical Center Pathology Department

GOALS AND OBJECTIVES BREAST PATHOLOGY

Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-

Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma

ACTG Laboratory Technologist Committee Revised Version 2.0 ACTG Lab Man Coulter HIV-1 p24 ELISA May 21, 2004

Overview of Wet Preps and Gram stains. Lorna Rabe Central Lab Magee-Womens Research Institute Pittsburgh, Pa

SMH (Myosin, smooth muscle heavy chain)

Human Cathepsin D ELISA Kit

IHC Stainer platforms. Overview, pros and cons

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry

LIST OF ORGANS FOR HISTOPATHOLOGICAL ANALYSIS:!! Neural!!!!!!Respiratory:! Brain : Cerebrum,!!! Lungs and trachea! Olfactory, Cerebellum!!!!Other:!

IMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA

Her-2/neu expression and its correlation with ER status and various clinicopathological parameters

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:

CaseBuilder - Quick Reference Guide

microrna Presented for: Presented by: Date:

'"-Reginald Co~t;~-~- REVIS"ED NEWfi-RELEA"SE--'" "

Supplementary Online Content

Digital Pathology and CAP Guidelines

Evolution of Pathology

A712(19)- Test slide, Breast cancer tissues with corresponding normal tissues

Citation Acta Medica Nagasakiensia. 1992, 37

Worksheet. Worksheet. Worksheet. Worksheet. Student Performance Guide. Student Performance Guide

CD15 and CEA expression in thymic epithelial neoplasms

Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2

An Investigation of Cellular Proliferation and Nuclear Morphology in the Multi-Step Progression of Cutaneous Squamous Cell Carcinoma

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients

Mouse GLP-2 EIA. Cat. No. KT-374. For the quantitative determination of GLP-2 in mouse serum or plasma. For Research Use Only. 1 Rev.

Prostate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue

Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment

Diagnosis of thoracic endometriosis with immunohistochemistry

Human Thyroid-Peroxidase Antibody, TPO-Ab ELISA Kit

SIV p27 Antigen ELISA Catalog Number:

Results you can trust

HercepTest for the Dako Autostainer Code K5207

Technique and feasibility of a dual staining method for estrogen receptors and AgNORs

Pathology Specimen Handling Requirements

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Human HIV (1+2) antigen&antibody ELISA Kit

BREAST CANCER PATHOLOGY

Rat cholesterol ELISA Kit

CAPILLARYS HEMOGLOBIN

Mouse Cathepsin B ELISA Kit

Mouse TrkB ELISA Kit

Potential Value of Hormone Receptor Assay in Carcinoma In Situ of Breast

FAQs for UK Pathology Departments

Preface 1. Fixation and Processing 1

Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY

Vaccination Setup. Immunization Set Up & Reporting

-26- MATERIALS AND METHODS

INSTRUCTION MANUAL FOR HBsAg SUBTYPE EIA

Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine

SURGICAL PATHOLOGY - HISTOLOGY STAINING MANUAL - NERVE TISSUE Page: 1 of 3 BODIAN'S METHOD - NERVE FIBERS PURPOSE: For demonstrating nerve fibers.

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex anti-hcv (version 4.0) Number: PQDx

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.

Basement membrane in lobule.

ISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS

Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice

PD-L1 IHC 22C3 pharmdx. SK tests for use with Autostainer Link 48 Table of Contents

ab Colon cancer tissue array of 228 cases (1.1mm)

APPENDIX 1 ETHICAL CLEARANCE

Novocastra Liquid Mouse Monoclonal Antibody MyoD1 (Rhabdomyosarcoma Marker)

ACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION

Anti-PD-L1 antibody [28-8] ab205921

Mapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery

Yara Saddam. Amr Alkhatib. Ihsan

Evaluation of the diagnostic value of immunocytochemistry and in situ hybridization in the pediatric leprosy

Epithelial cell-cell adhesion molecule (Ep-CAM)

Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma

ab Cathepsin D Human ELISA Kit

Melanin Bleaching with Warm Hydrogen Peroxide and Integrated Immunohistochemical Analysis: An Automated Platform

HER2 Testing of Multifocal Invasive Breast Carcinoma. Gillian C. Bethune, MD, J. Brendan Mullen, MD, and Martin C. Chang, MD, PhD

Laboratory Procedure Manual

Assessment Run GATA3

Transcription:

Message CIHRT Exhibit P-1830 Page 1 Page 1 of 1 Wpc1 From: Sent: To: Cc: Subject: Mendes, Maria Friday, April 20, 2007 3:43 PM Mullen, Dr. Brendan Kuruzar, Gordana; Ni, Ruoyu; D Mello, Vince ER/PR Newfoundland Attachments: IHe ERPR SOP.doc; ERPR SOP.doc; Dr. Mullen.xls; ER Protocol.doc; PR Protocol.doc Hi Dr. Mullen, SOP. I had sent Newfoundland on a previous occasion. Gordana will add the clone # to the which dilution since there was some adjustments made when we changed instruments. This was the information I have also attached the the excel sheet showing all your results as well as which instrument was used and Let me know if this looks OK I Maria will send it to the person requesting the information. 12/8/2007

CIHRT Exhibit P-1830 Page 2 Toronto, Canada M5G IXI MOUNT SINAI HOSPITAL ERiPR Immunohistochemistry (IHC) Standard Operating Procedure Special Histology Hard Tissue Procedure Manual Project Specific Protocol - - - - - - - - Dr. - - - - -.Date: - Brendan Mullen Date: Authorization by Study Director: Written by: - _ C:\Documents and Settings\wpc1 \Local Settings\Temporary Intemet Page 1 of7

CIHRT Exhibit P-1830 Page 3 Toronto, Canada M5G IXI - Flowchart Principle of me Detection Systems Methodologies Automated Table of Contents Quality Control 7 3 4 4 4 C:\Documents and Settings\wpcl \Local Settings\Temporary Intemet Page 2 of7

CIHRT Exhibit P-1830 Page 4 Toronto, Canada M5G IXI Overview Flowchart - Autostainer Receive labeledimmuno unstained slides and H&E slides from Special Histology Laboratory - Neg. sort runs according to: antibody pretreatment detection system Run -Positive antibodies with controls AB. control per control for detection system Collate stained immuno slides with H&E s QC Compare each slide to block & H&E Give Slides to Pathologist C:\Documents and Settings\wpc1 \Local Settings\Temporary Internet Page 3 of7

Toronto, Canada M5G IXI Principles of Immunohistochemistry: Refer to Histology/Immunohistochemistry procedure manual SOP# 3:Principles of Immullohistochemistry Detection Systems: Optimal antibody titer and detection system are predetermined for each of the antibodies to be run and the information recorded. - Methodologies Automated IHe Method: Programming the Autostainer LabVision 720: All information regarding antibody titer and detection system used is preprogrammed First few runs (refer Attached Excel Sheet) are run on DAKO Autostainer (refer Histology/Immunohistochemistry SOP). After validation and correction of Antibody dilution the project is continued on LabVision Autostainer 720. into the computer in the protocol template. (refer to Labvision manual, section 13.6.1 Creating a New Staining Program). Organization of Slides: Group the slides in accordance with the antibody,stated on the QC Antibody chart. Both antibodies (ER and PR) using Horse anti-mouse (HAM)/Elite-ABC detection system and grouped together on the same run. Positive controls for each antibody are included. The decision to use negative controls for every block is left up to the discretion of the pathologist. (refer to Attached Excel sheet). CIHRT Exhibit P-1830 Page 5 C:\Documents and Settings\wpc I\Local Settings\Temporary Intemet Page 4 of7

CIHRT Exhibit P-1830 Page 6 Toronto, Canada M5G IXI Pretreatment: Blocking endogenous pigments: Interstitial peroxidase activity may be present in the tissue sections. In order to suppress endogenous peroxidase activity in formalin fixed tissue, perform the following: Deparaffinize the slides and take down to water using descending grades of alcohol. peroxide for a 15 minutes. Wash well in 2 changes of tap water. Block the endogenous peroxidase activity by using a 3% aqueous solution of hydrogen Antigen Retrieval: In order to unmask the antigen sites the Microwave Antigen Retrieval method is The method can be found in the Histolgy/l11l11lllllohistochemistry procedure manual employed using the Micromed 9.0 TT Mega with Tris Buffer ph for both the antibodies. SOP#4. Blocking of Non-Specific binding of Endogenous AvidinfBiotin Activity Biotin is distributed in a wide variety of tissues. These tissues may bind avidin, biotinylated horseradish peroxidase or other Biotin!Avidin system components which cause non-specific binding. This occurrence can be suppressed by adding Avidin to the normal blocking semm and biotin to the primary. Setting up the grid and map on the Autostainer: The autostainer capacity is 84 slides depending on the number of antibodies and the number of detection systems used. Program the autostainer with the number of slides for the antibodies being nm. The detection system infom1ation is pre-programmed into the computer. The software devises a map and a grid of the antibodies to be tested. The map and the grid for each mn are saved, printed out, and logged. C:\Documents and Settings\wpcl \Local Settings\Temporary Intemet Page 5 of7

Toronto, Canada M5G IX1 Preparing reagents for the Run Antibody Preparation: The optimal dilutions (refer Routine Antibody Data Sheet) of the primary antibodies are made up according to the volumes stated on the Reagent map. The primary antibodies are diluted in Antibody diluent with the addition of Biotin. The quantities are prepared fresh for each run. The blocking serum plus Avidin, the secondary and the tertiary antibodies are made up in Tris buffered saline and measured into the reagent vials according to the volumes stated on the reagent map. Loading the Autostainer CIHRT Exhibit P-1830 Page 7 The slides are loaded in the autostainer in accordance with the map. The positions of the reagent vials in the rack are checked against the map. Completing the Staining Run At the end of the staining run, save the Run Log. Remove the slides from the machine. Click on the Clean button to TIm the clean cycle. Counterstaining the slides Wash the slides in TImning water for a few seconds. Countrastain in Mayer s Hematoxylin, followed by washing in warm running water. 10-20 Differentiate seconds in Scott s Tap Water followed by washing in wann rumling water. Dehydrate clear and mount. The slides are then collated with their coltesponding Hematoxylin and Eosin stained slide. C:\Documents and Settings\wpc1 \Local Settings\Temporary Internet Page 6 of7

CIHRT Exhibit P-1830 Page 8 Toronto, Canada M5G IXI Quality Control The quality control performed for the project is in compliance with standard laboratory practices (refer to Histoiogy/Immullohistochemistry procedure mallual SOP#l 0 Quality COlltrol Program). Each antibody tested is run with a positive control. Negative controls were run on each patient block at the beginning of the project. After Pathologist review it was decided that no Negative control per block would be required. Instead there was one Negative control per run (refer to Attached Excel Chart). The control slides are dated along with the test slides that are run in the same batch and the positive control slides are filed in the laboratory archive. The Negative control slides / per block! are filed with the test project slides. The Negative control slide /per run/ will be kept at our location. Upon completion of staining, each IHC stained slide is compared to the block it was cut from and its corresponding H&E slide. Each slide stained is checked microscopically for stain and section quality this is recorded on the ERiPR QC sheet. All discrepancies that arise during processing, cutting, and staining are recorded on a "Quality Assurance Problem Sheet." The description of the problem and the follow-up and/or corrective action are included on this document. These sheets are kept in the "QC Documentation 2005" project binder. C:\Documents and Settings\wpcl \Local Settings\Temporary Intemet Page70f7

CIHRT Exhibit P-1830 Page 9 ER/PR Retrospective Study, Special Histology, Hard Tissue Division, Toronto, Canada M5G lx5 MOUNT SINAI HOSPITAL ERiPR S.O.P. FOR ERIPR RETROSPECTIVE STUDY Special Histology Hard Tissue Procedure Manual Project Specific Protocol Authorization ----------- by Study Director: Dr. Date: Brendan - - Mullen - - - - - Written by: Date: _ C:\Documents and Settings\wpcl\Local Settings\Telllporary lntemet Files\OLK2CBC\ERPR SOP (G).doc

ER/PR Retrospective Study, Special Histology, Hard Tissue Division, Toronto, Canada M5G lx5 SPECIMEN RECEIVING All specimens were received in clear transpoli bags with the surgical report and the coltesponding block(s). Specimens were accessioned and given an RS number (indicating the research laboratory) and labels were affixed to the attached surgical repoli and the wax block(s). Any block/surgical number discrepancies, however minor, were noted on an Excel spreadsheet and the requesting hospital was notified via e-mail. An Excel spreadsheet was created to document the following infolmation: RS#, specimen# (requesting hospital s surgical number), patient name, block(s) received and site. Slide box numbers (storage for stained slides) were also noted on this spreadsheet along with ERJPR results and staining infonnation. Another Excel spreadsheet was created listing specimens that were requested for HER 2 neu staining and specimens that were to be taken out of the retrospective study and treated as a routine surgical consult. These blocks were retumed upon completion of the surgical report. The blocks in the retrospective study were kept at Mount Sinai until notification was received to return all blocks, along with stained slides. SPECIMEN PROCESSING Specimens did not require processing, as wax blocks were received. CUTTING AND STAINING All wax blocks were cut in accordance with immunohistochemical procedures. Blocks were cut at 4 microns, picked up onto 6 RS# labeled charged slides (H&E, ER, PR, negative control and 2 spare slides), rolled and melted briefly on a 60 D C hotplate. Cut slides were then dried in a 37 D C oven overnight and stained the following day. Slides that were not stained were stored at 4DC until required. Refer to the Research IHC Standard Operating Procedure for ERJPR for staining overview. PAPERWORK CIHRT Exhibit P-1830 Page 10 Results were e-mailed via the Excel spreadsheet as they became available. All Excel spreadsheets listing specimens received, block discrepancies and consults will be printed out and sent out along with the stained slides and blocks via FedEx. C:\Documents and Settings\wpc 1\Local Settings\Telllporary Intelllet Files\OLK2CBC\ERPR SOP (G).doc

- our - your - patient s ER/PR Retrospective Study, Special Histology, Hard Tissue Division, Toronto, Canada M5G IX5 - - PATHOLOGIST COMPONENT The code used is as follows: RS# research number SPECIMEN# case number PATIENT NAME name BLOCK block number supplied COMMENTS discrepancies in block infonnation/hospital of origin Tumour = tumour type with the following descriptions: D = ductal = DL ductal with lobular features DT = ductal with tubular features = L lobular = PAP papillary DCIS = DCISJ]VI = C = colloid T = tubular ductal carcinoma in situ ductal carcinoma in situ with microinvasion lmm).mca = metastatic CA encysted papillary in situ carcinoma ductal carcinoma with apocrine features EIC = extensive DCIS (>25%), = M metaplastic carcinoma AC = adenoid cystic carcinoma CaNOS = unclassified carcinoma EPAP = DA = CIHRT Exhibit P-1830 Page 11 C:\Doculllcnts and Scttings\wpcl\Local Settings\Temporary Internet Files\OLK2CBC\ERPR SOP (G).doc

ER/PR Retrospective Study, Special Histology, Hard Tissue Division =, Toronto, Canada M5G lx5 PU pickup with tumour adherent to tissue = NT no tumour ER = % cells positive 6Fll, LSAB procedure % cells positive PGRl294, LSAB procedure PR = Ie = P = internal controls with the following comments: present but not stained PS = present and stained PSW = present and stained weakly A = absent F/P = fixation and processing with the following comments: A = P = adequate and poor CIHRT Exhibit P-1830 Page 12 Threshold for positive ERiPR result: staining of any intensity in > 1% invasive tumour cells Positive and negative laboratory external controls stained appropriately C:\Documents and Settings\wpc 1\Local Settings\Temporary Internet Files\OLK2CBC\ERPR SOP (6).doc